Phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) in adults with newly diagnosed (ND) Philadelphia chromosome–negative (Ph-) B lymphoblastic leukemia (B-ALL).

Noam E. Kopmar, Ryan D. Cassaday, Noah Pinke et al.|Journal of Clinical Oncology|2026

Cited by 0